2025 Q4 -tulosraportti
Vain PDF
5 päivää sitten
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 889 | - | - | ||
| 1 066 | - | - | ||
| 934 | - | - | ||
| 24 | - | - | ||
| 1 733 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·3 min sittenBREAKING. LILLY BUYS YET ANOTHER IN VIVO CAR-T COMPANY. 🚨🧬 $7 billion. Announced today. Eli Lilly has just signed an agreement to acquire Kelonia Therapeutics for up to $7 billion. It is the third major in vivo CAR-T acquisition in under one year. Orna ($2.4bn). Orbital to BMS ($1.5bn). And now Kelonia ($7bn). The arms race is not starting. It's already in full swing. And we are sitting here with the Acuitas partnership, the Big Pharma deal, the Boston platform and runway until 2030. While the giants are desperately buying into the technology – we are already working with the people behind it. We know what we own. ♟️🧱🍷
·5 min sitten · MuokattuAs you may have noticed, it has happened again: yet another acquisition of an early-stage platform-based biotech company. Tonight, I have thoroughly familiarized myself with Eli Lilly's acquisition of Kelonia Therapeutics and what it could mean for Circio. This is something the industry will definitely take notice of, and I would like to share some reasons why Circio's shareholders should do the same. In short, Kelonia Therapeutics has developed a platform that delivers genetic instructions directly to the body's T-cells. The goal is to turn T-cells into CAR-T cells, by equipping the T-cells with an extra receptor that tells them what to attack (cancer) and how to carry out the attack (target the cancer cell's surface protein). For those of you who don't know what T-cells are, they are simply white blood cells that form an important part of the body's immune system. Highly relevant in cancer treatment. This is living medicine. In common with Kelonia, Circio also works in the CAR-T field together with Acuitas Therapeutics. We learned this last week, without much reaction from the market. While Kelonia Therapeutics focuses on delivering instructions and genetic modification of T-cells, Circio can potentially contribute to how strongly, effectively, and how long gene expression lasts. This has until now been a huge challenge in cell/gene therapy and RNA medicine (mRNA). Circio could potentially hold the solution through its platform technology circVec and the application of circular RNA (circRNA). In other words, Circio's platform is highly complementary if circVec and Kelonia's platform are combined to deliver the cancer medicine of the future in its entirety. Eli Lilly is guaranteed to be interested and is paying attention. As an extra bonus, we must not forget that Circio also works with United Immunity and their CAR-M program. CAR-M are modified macrophages, which are also a type of white blood cell. While T-cells kill, macrophages take and remove cellular waste (such as dead cancer cells). CAR-M is quite new and a further development of the CAR-T field. The most important thing about today's news for us as shareholders in Circio is that the acquisition further validates the field in which Circio has positioned itself. In vivo CAR-T is extremely hot right now, circular RNA is extremely hot right now, and circVec testing within CAR-T is now becoming even more important and relevant. Investors looking for the next "big thing" will now see that significant value in biotech lies in platform technology, as well as data and strategic position. Circio scores 3/3 here. Today's acquisition proves once again that valuations between 20 and 70 billion NOK are happening here and now in early-stage platform-based biotech (Orna: preclinical, Kelonia: phase 1). Circio has through several agreements shown that they are no longer an insignificant player in a fantasy world, but that they are actually working with major players in a field that is highly sought after and relevant as of today. This increases Circio's credibility and should increase international interest in the long term.
·1 t sittenIt says here in Yahoo Finance: https://finance.yahoo.com/sectors/healthcare/articles/eli-lilly-expands-genetic-medicine-150500007.html
·38 min sittenI have also used ChatGPT quite a bit to try to better understand the Circio case, and I must admit that much of what I have previously shared in terms of Circio-related news, it has been quite reserved about. But when I shared exactly this news about Kelonia, I got a slightly different answer. Here's what it says: "Yes, this acquisition is relevant. It must be seen in the context of the two previous transactions in the same segment: Orbital (~1.5 bn USD) and Orna (up to ~2.4 bn USD). With Kelonia, a larger transaction of up to ~7 bn USD is now added, where ~3.25 bn is upfront. This confirms a clear trend: large pharmaceutical companies are actively moving into this area, especially within in vivo cell therapy and genetic treatment modalities. In vivo is considered strategically important because the treatment occurs directly in the body, which makes it more scalable than traditional ex vivo solutions. This is an area where several players are now competing for position. At the same time, it is important to distinguish between the maturity levels in the cases. Kelonia is in a clinical phase with human data. Orna had a concrete CAR-T program. Orbital was also more mature. Circio is still in an earlier phase, mainly with data from animal models. Such acquisitions can help accelerate the pace in the field, because buyers are already active and looking for relevant technologies. This makes future milestones more important. Abstract and ASGCT function as a first quality filter. Further data will be crucial for real validation, and partner progression will provide external confirmation. The conclusion is that this is positive for the sector and the direction Circio operates in, but that the greatest values are only realized when the technology is validated through more extensive data."- ·1 t sittenLILLY TO ACQUIRE KELONIA THERAPEUTICS TO ADVANCE IN VIVO CAR-T-CELL THERAPIES April 20, 2026 Under the agreement, Lilly will acquire Kelonia, and Kelonia's shareholders will receive up to 7.00 billion dollars in cash, including an upfront payment of 3.25 billion dollars, and subsequent payments upon achievement of certain clinical, regulatory, and commercial milestones. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-kelonia-therapeutics-advance-vivo-car-t-cell
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
Vain PDF
5 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 min sittenBREAKING. LILLY BUYS YET ANOTHER IN VIVO CAR-T COMPANY. 🚨🧬 $7 billion. Announced today. Eli Lilly has just signed an agreement to acquire Kelonia Therapeutics for up to $7 billion. It is the third major in vivo CAR-T acquisition in under one year. Orna ($2.4bn). Orbital to BMS ($1.5bn). And now Kelonia ($7bn). The arms race is not starting. It's already in full swing. And we are sitting here with the Acuitas partnership, the Big Pharma deal, the Boston platform and runway until 2030. While the giants are desperately buying into the technology – we are already working with the people behind it. We know what we own. ♟️🧱🍷
- ·5 min sitten · MuokattuAs you may have noticed, it has happened again: yet another acquisition of an early-stage platform-based biotech company. Tonight, I have thoroughly familiarized myself with Eli Lilly's acquisition of Kelonia Therapeutics and what it could mean for Circio. This is something the industry will definitely take notice of, and I would like to share some reasons why Circio's shareholders should do the same. In short, Kelonia Therapeutics has developed a platform that delivers genetic instructions directly to the body's T-cells. The goal is to turn T-cells into CAR-T cells, by equipping the T-cells with an extra receptor that tells them what to attack (cancer) and how to carry out the attack (target the cancer cell's surface protein). For those of you who don't know what T-cells are, they are simply white blood cells that form an important part of the body's immune system. Highly relevant in cancer treatment. This is living medicine. In common with Kelonia, Circio also works in the CAR-T field together with Acuitas Therapeutics. We learned this last week, without much reaction from the market. While Kelonia Therapeutics focuses on delivering instructions and genetic modification of T-cells, Circio can potentially contribute to how strongly, effectively, and how long gene expression lasts. This has until now been a huge challenge in cell/gene therapy and RNA medicine (mRNA). Circio could potentially hold the solution through its platform technology circVec and the application of circular RNA (circRNA). In other words, Circio's platform is highly complementary if circVec and Kelonia's platform are combined to deliver the cancer medicine of the future in its entirety. Eli Lilly is guaranteed to be interested and is paying attention. As an extra bonus, we must not forget that Circio also works with United Immunity and their CAR-M program. CAR-M are modified macrophages, which are also a type of white blood cell. While T-cells kill, macrophages take and remove cellular waste (such as dead cancer cells). CAR-M is quite new and a further development of the CAR-T field. The most important thing about today's news for us as shareholders in Circio is that the acquisition further validates the field in which Circio has positioned itself. In vivo CAR-T is extremely hot right now, circular RNA is extremely hot right now, and circVec testing within CAR-T is now becoming even more important and relevant. Investors looking for the next "big thing" will now see that significant value in biotech lies in platform technology, as well as data and strategic position. Circio scores 3/3 here. Today's acquisition proves once again that valuations between 20 and 70 billion NOK are happening here and now in early-stage platform-based biotech (Orna: preclinical, Kelonia: phase 1). Circio has through several agreements shown that they are no longer an insignificant player in a fantasy world, but that they are actually working with major players in a field that is highly sought after and relevant as of today. This increases Circio's credibility and should increase international interest in the long term.
- ·1 t sittenIt says here in Yahoo Finance: https://finance.yahoo.com/sectors/healthcare/articles/eli-lilly-expands-genetic-medicine-150500007.html·38 min sittenI have also used ChatGPT quite a bit to try to better understand the Circio case, and I must admit that much of what I have previously shared in terms of Circio-related news, it has been quite reserved about. But when I shared exactly this news about Kelonia, I got a slightly different answer. Here's what it says: "Yes, this acquisition is relevant. It must be seen in the context of the two previous transactions in the same segment: Orbital (~1.5 bn USD) and Orna (up to ~2.4 bn USD). With Kelonia, a larger transaction of up to ~7 bn USD is now added, where ~3.25 bn is upfront. This confirms a clear trend: large pharmaceutical companies are actively moving into this area, especially within in vivo cell therapy and genetic treatment modalities. In vivo is considered strategically important because the treatment occurs directly in the body, which makes it more scalable than traditional ex vivo solutions. This is an area where several players are now competing for position. At the same time, it is important to distinguish between the maturity levels in the cases. Kelonia is in a clinical phase with human data. Orna had a concrete CAR-T program. Orbital was also more mature. Circio is still in an earlier phase, mainly with data from animal models. Such acquisitions can help accelerate the pace in the field, because buyers are already active and looking for relevant technologies. This makes future milestones more important. Abstract and ASGCT function as a first quality filter. Further data will be crucial for real validation, and partner progression will provide external confirmation. The conclusion is that this is positive for the sector and the direction Circio operates in, but that the greatest values are only realized when the technology is validated through more extensive data."
- ·1 t sittenLILLY TO ACQUIRE KELONIA THERAPEUTICS TO ADVANCE IN VIVO CAR-T-CELL THERAPIES April 20, 2026 Under the agreement, Lilly will acquire Kelonia, and Kelonia's shareholders will receive up to 7.00 billion dollars in cash, including an upfront payment of 3.25 billion dollars, and subsequent payments upon achievement of certain clinical, regulatory, and commercial milestones. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-kelonia-therapeutics-advance-vivo-car-t-cell
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 889 | - | - | ||
| 1 066 | - | - | ||
| 934 | - | - | ||
| 24 | - | - | ||
| 1 733 | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
2025 Q4 -tulosraportti
Vain PDF
5 päivää sitten
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 31.8. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 15.4. | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·3 min sittenBREAKING. LILLY BUYS YET ANOTHER IN VIVO CAR-T COMPANY. 🚨🧬 $7 billion. Announced today. Eli Lilly has just signed an agreement to acquire Kelonia Therapeutics for up to $7 billion. It is the third major in vivo CAR-T acquisition in under one year. Orna ($2.4bn). Orbital to BMS ($1.5bn). And now Kelonia ($7bn). The arms race is not starting. It's already in full swing. And we are sitting here with the Acuitas partnership, the Big Pharma deal, the Boston platform and runway until 2030. While the giants are desperately buying into the technology – we are already working with the people behind it. We know what we own. ♟️🧱🍷
- ·5 min sitten · MuokattuAs you may have noticed, it has happened again: yet another acquisition of an early-stage platform-based biotech company. Tonight, I have thoroughly familiarized myself with Eli Lilly's acquisition of Kelonia Therapeutics and what it could mean for Circio. This is something the industry will definitely take notice of, and I would like to share some reasons why Circio's shareholders should do the same. In short, Kelonia Therapeutics has developed a platform that delivers genetic instructions directly to the body's T-cells. The goal is to turn T-cells into CAR-T cells, by equipping the T-cells with an extra receptor that tells them what to attack (cancer) and how to carry out the attack (target the cancer cell's surface protein). For those of you who don't know what T-cells are, they are simply white blood cells that form an important part of the body's immune system. Highly relevant in cancer treatment. This is living medicine. In common with Kelonia, Circio also works in the CAR-T field together with Acuitas Therapeutics. We learned this last week, without much reaction from the market. While Kelonia Therapeutics focuses on delivering instructions and genetic modification of T-cells, Circio can potentially contribute to how strongly, effectively, and how long gene expression lasts. This has until now been a huge challenge in cell/gene therapy and RNA medicine (mRNA). Circio could potentially hold the solution through its platform technology circVec and the application of circular RNA (circRNA). In other words, Circio's platform is highly complementary if circVec and Kelonia's platform are combined to deliver the cancer medicine of the future in its entirety. Eli Lilly is guaranteed to be interested and is paying attention. As an extra bonus, we must not forget that Circio also works with United Immunity and their CAR-M program. CAR-M are modified macrophages, which are also a type of white blood cell. While T-cells kill, macrophages take and remove cellular waste (such as dead cancer cells). CAR-M is quite new and a further development of the CAR-T field. The most important thing about today's news for us as shareholders in Circio is that the acquisition further validates the field in which Circio has positioned itself. In vivo CAR-T is extremely hot right now, circular RNA is extremely hot right now, and circVec testing within CAR-T is now becoming even more important and relevant. Investors looking for the next "big thing" will now see that significant value in biotech lies in platform technology, as well as data and strategic position. Circio scores 3/3 here. Today's acquisition proves once again that valuations between 20 and 70 billion NOK are happening here and now in early-stage platform-based biotech (Orna: preclinical, Kelonia: phase 1). Circio has through several agreements shown that they are no longer an insignificant player in a fantasy world, but that they are actually working with major players in a field that is highly sought after and relevant as of today. This increases Circio's credibility and should increase international interest in the long term.
- ·1 t sittenIt says here in Yahoo Finance: https://finance.yahoo.com/sectors/healthcare/articles/eli-lilly-expands-genetic-medicine-150500007.html·38 min sittenI have also used ChatGPT quite a bit to try to better understand the Circio case, and I must admit that much of what I have previously shared in terms of Circio-related news, it has been quite reserved about. But when I shared exactly this news about Kelonia, I got a slightly different answer. Here's what it says: "Yes, this acquisition is relevant. It must be seen in the context of the two previous transactions in the same segment: Orbital (~1.5 bn USD) and Orna (up to ~2.4 bn USD). With Kelonia, a larger transaction of up to ~7 bn USD is now added, where ~3.25 bn is upfront. This confirms a clear trend: large pharmaceutical companies are actively moving into this area, especially within in vivo cell therapy and genetic treatment modalities. In vivo is considered strategically important because the treatment occurs directly in the body, which makes it more scalable than traditional ex vivo solutions. This is an area where several players are now competing for position. At the same time, it is important to distinguish between the maturity levels in the cases. Kelonia is in a clinical phase with human data. Orna had a concrete CAR-T program. Orbital was also more mature. Circio is still in an earlier phase, mainly with data from animal models. Such acquisitions can help accelerate the pace in the field, because buyers are already active and looking for relevant technologies. This makes future milestones more important. Abstract and ASGCT function as a first quality filter. Further data will be crucial for real validation, and partner progression will provide external confirmation. The conclusion is that this is positive for the sector and the direction Circio operates in, but that the greatest values are only realized when the technology is validated through more extensive data."
- ·1 t sittenLILLY TO ACQUIRE KELONIA THERAPEUTICS TO ADVANCE IN VIVO CAR-T-CELL THERAPIES April 20, 2026 Under the agreement, Lilly will acquire Kelonia, and Kelonia's shareholders will receive up to 7.00 billion dollars in cash, including an upfront payment of 3.25 billion dollars, and subsequent payments upon achievement of certain clinical, regulatory, and commercial milestones. https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-kelonia-therapeutics-advance-vivo-car-t-cell
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 5 889 | - | - | ||
| 1 066 | - | - | ||
| 934 | - | - | ||
| 24 | - | - | ||
| 1 733 | - | - |
Välittäjätilasto
Dataa ei löytynyt